Sodium salicylate (NaS) and aspirin (ASA) are known to have a variety of effects on microorganisms, such as fungus (C. albicans and C. neoformans), moreover, it have effects in leukocyte adhesion and migration in vitro. In this report, we investigated the effect of ASA and NaS in neutrophil migration and cytokine production in C. albicans-induced peritonitis murine model. For this, mice were treated intraperitoneally (i.p) or orally (po) with NaS or ASA; after they were stimulated i.p. with C. albicans, the cellular migration was evaluated 24 h after stimulation. NaS, in mice treated i.p., unlike ASA, was able to inhibit the neutrophil migration and proinflammatory cytokine production induced by C. albicans, such as TNF-α, IL-1, IFN-γ, IL-12, and IL-10, but did not alter the IL-4 levels in these animals. However, the po treatment with same the dose of NaS or ASA did not affect the influx of this cell for inflammatory site. These results suggest that the NaS inhibits cellular migration and proinflammatory cytokine by different anti-inflammatory mechanism compared to ASA.

Departamento de Análises Clínicas Toxicológicas e Bromatológicas Faculdade de Ciências Farmacêuticas de Ribeirão Preto USP SP Ribeirão Preto Brazil

Departamento de Anatomia Patológica Universidade Federal do Paraná PR Paraná Brazil

Departamento de Biologia Universidade Estadual do Centro Oeste UNICENTRO Guarapuava PR Brazil

Departamento de Bioquímica e Imunologia Faculdade de Medicina de Ribeirão Preto USP SP Ribeirão Preto Brazil

Endereço Laboratório de Microbiologia e Imunologia Clínica Faculdade de Farmácia Instituto de Ciências da Saúde Universidade Federal do Pará UFPA Rua Augusto Correia Belém PA Brazil

Pós graduação em Ciências Farmacêuticas Pós graduação em Neurociências e Biologia celular Faculdade de Farmácia Instituto de Ciências da Saúde Universidade Federal do Pará UFPA Rua Augusto Correia Belém PA Brazil

See more in PubMed

J Pharm Sci. 1972 Mar;61(3):379-85 PubMed

Dan Med J. 2013 Nov;60(11):B4698 PubMed

Acta Derm Venereol. 2012 May;92(3):291-8 PubMed

J Leukoc Biol. 2015 Oct;98 (4):539-48 PubMed

J Gastroenterol. 2016 Jul;51(7):691-701 PubMed

Nat Rev Immunol. 2004 Jan;4(1):1-23 PubMed

Br J Clin Pharmacol. 1980 Oct;10 Suppl 2:285S-290S PubMed

Clin Microbiol Rev. 2003 Jul;16(3):517-33 PubMed

Cytokine. 2012 Apr;58(1):118-28 PubMed

Drug Chem Toxicol. 1998 Nov;21(4):507-20 PubMed

Cardiovasc Hematol Disord Drug Targets. 2015;15(1):19-28 PubMed

Circ Res. 1996 May;78(5):759-68 PubMed

Int J Nanomedicine. 2010 Oct 05;5:771-81 PubMed

Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14540-5 PubMed

Br J Haematol. 1975 Feb;29(2):273-8 PubMed

Metabolism. 1982 Oct;31(10):1014-22 PubMed

Diabetes. 2002 Jun;51(6):1772-8 PubMed

Blood. 1998 Oct 1;92(7):2389-98 PubMed

Biomed Pharmacother. 2007 Feb-Apr;61(2-3):148-53 PubMed

Microbes Infect. 2006 Apr;8(5):1219-26 PubMed

Nat Rev Microbiol. 2008 Jan;6(1):67-78 PubMed

Science. 1995 Dec 22;270(5244):2017-9 PubMed

Curr Opin Crit Care. 2010 Oct;16(5):453-9 PubMed

Dig Dis Sci. 1995 Jan;40(1):134-40 PubMed

Iran J Immunol. 2013 Jun;10(2):118-26 PubMed

Cell Microbiol. 2006 Apr;8(4):668-76 PubMed

Nature. 1996 May 2;381(6577):77-80 PubMed

J Pharmacol Exp Ther. 2002 Jun;301(3):969-74 PubMed

Braz J Infect Dis. 2014 May-Jun;18(3):287-93 PubMed

J Biol Chem. 1988 Apr 15;263(11):5380-4 PubMed

Blood. 2014 Jul 31;124(5):710-9 PubMed

Eur J Pharmacol. 2002 Jan 2;434(1-2):65-70 PubMed

Blood. 2011 Jun 2;117(22):5881-91 PubMed

J Immunol. 1988 Oct 1;141(7):2388-93 PubMed

Folia Microbiol (Praha). 2011 Jul;56(4):349-52 PubMed

Br J Pharmacol. 2013 Jan;168(1):225-37 PubMed

J Cell Biochem. 2013 Aug;114(8):1729-37 PubMed

Prostaglandins Other Lipid Mediat. 2012 Jan;97(1-2):66-71 PubMed

Cell Mol Immunol. 2012 May;9(3):276-86 PubMed

Infect Immun. 2004 May;72(5):2939-46 PubMed

Front Biosci (Landmark Ed). 2014 Jun 01;19:1279-90 PubMed

Curr Opin Infect Dis. 2013 Jun;26(3):270-6 PubMed

Mediators Inflamm. 2013;2013:950981 PubMed

Ann Rheum Dis. 1985 Oct;44(10):694-700 PubMed

Support Care Cancer. 1997 May;5(3):249-51 PubMed

J Surg Res. 1999 Jun 15;84(2):143-9 PubMed

Gen Pharmacol. 1989;20(2):151-5 PubMed

Int J Immunopathol Pharmacol. 2013 Jul-Sep;26(3):663-72 PubMed

Microbes Infect. 2010 Jul;12(7):518-27 PubMed

Proc Natl Acad Sci U S A. 1987 Mar;84(5):1417-20 PubMed

Microbes Infect. 2003 Nov;5(14):1289-91 PubMed

Mol Pharmacol. 1997 Sep;52(3):398-405 PubMed

Immunology. 1995 Mar;84(3):446-52 PubMed

Leuk Res. 2012 May;36(5):570-4 PubMed

J Clin Invest. 1978 Feb;61(2):349-59 PubMed

Blood. 1995 Oct 1;86(7):2541-50 PubMed

J Pharm Pharmacol. 1976 Aug;28(8):655-6 PubMed

Drug Metab Rev. 1979;9(1):3-19 PubMed

J Mycol Med. 2014 Jun;24(2):135-40 PubMed

Blood. 1979 May;53(5):1018-22 PubMed

Arch Med Res. 1993 Winter;24(4):361-9 PubMed

Pol J Pharmacol. 2003 Mar-Apr;55(2):209-12 PubMed

Prostaglandins. 1981;21 Suppl:139-46 PubMed

Br J Pharmacol. 1988 Apr;93(4):937-43 PubMed

Eur J Pharmacol. 2002 Jun 28;447(1):1-9 PubMed

J Leukoc Biol. 1996 Jun;59(6):840-6 PubMed

Curr Drug Targets. 2005 Dec;6(8):863-74 PubMed

Cell Microbiol. 2004 Nov;6(11):1085-96 PubMed

Eur J Pharmacol. 2010 Jul 25;638(1-3):13-20 PubMed

J Immunol. 2009 Aug 1;183(3):2089-96 PubMed

J Antimicrob Chemother. 1999 Jul;44(1):57-64 PubMed

J Immunol. 1996 May 15;156(10 ):3961-9 PubMed

Ann Parasitol. 2013;59(2):57-66 PubMed

J Microbiol. 2013 Oct;51(5):598-604 PubMed

Biochemistry (Mosc). 2014 Dec;79(12):1286-96 PubMed

Exp Parasitol. 2002 Nov-Dec;102(3-4):170-7 PubMed

Biochim Biophys Acta. 2015 Apr;1851(4):414-21 PubMed

Clin Dev Immunol. 2011;2011:686597 PubMed

Med Mycol. 2011 May;49(4):380-94 PubMed

Shock. 2014 Oct;42(4):286-94 PubMed

Antimicrob Agents Chemother. 2004 Jan;48(1):41-7 PubMed

FASEB J. 2002 Mar;16(3):438-40 PubMed

Infect Immun. 2002 Jan;70(1):400-2 PubMed

Arthritis Res Ther. 2013;15 Suppl 3:S3 PubMed

Microb Pathog. 2010 Dec;49(6):315-22 PubMed

Circulation. 2000 Oct 24;102(17):2022-3 PubMed

Nimesulide inhibits pathogenic fungi: PGE2-dependent mechanisms